Bartosz Puła

Submitted: 24 September 2026 Posted: 25 September 2026 You are already at the latest version Rosai-Dorfman-Destombes disease (RDD) is a rare histiocytic disorder also known as sinus histiocytosis with massive lymphadenopathy. While, for many years, RDD was considered a polyclonal, reactive, and non-neoplastic disease, the more recent discovery of activating alterations in MAPK-pathway genes such as KRAS, NRAS, MAP2K1 and ARAF supports its current classification as a histiocytic neoplasm.

ABSTRACT Introduction Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in adults. Although treatment has shifted from immunochemotherapy to novel targeted drugs over the last ten years, novel therapies remain under investigation, particularly in relapsed and refractory patients. Areas covered This review describes the use of approved targeted drugs and novel therapies in treatment-naïve and relapsed or refractory CLL.

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.